Scientists have identified a new potential solution for managing high cholesterol levels as an alternative to statins. The research reveals how excess cholesterol disrupts the liver’s natural defenses and introduces a promising medication to counteract this effect.
Despite the availability of statins like Atorvastatin and Simvastatin for controlling cholesterol and preventing heart disease, many patients still struggle to achieve safe cholesterol levels or tolerate the side effects of current medications. The study, published in Nature, unveils a hidden biological mechanism that explains how high cholesterol diets hinder the body’s ability to clear harmful LDL cholesterol from the bloodstream.
The research team from the University of California San Diego School of Medicine has identified a drug candidate that shows promise in addressing this issue. The study’s senior author, Professor Alan Saltiel, highlighted the importance of LDL receptors on liver cells in removing cholesterol from the blood. The new findings shed light on a pathway involving the protein Ral and the enzyme CTSA that affects LDL receptor stability and cholesterol levels.
By blocking CTSA with a small molecule inhibitor, researchers were able to stabilize LDL receptors and significantly reduce circulating LDL cholesterol in mice. This breakthrough offers a new avenue for developing cholesterol-lowering treatments beyond existing options like statins and PCSK9 inhibitors.
The investigational drug, originally intended for heart failure treatment, has already passed safety assessments in a Phase 1 clinical trial. Professor Saltiel sees great potential in moving this drug into a Phase 2 trial for high cholesterol treatment, expressing optimism about bringing a new therapeutic option to patients sooner than expected.
